DGCR6抗体—艾普蒂 新品

The DGCR6 antibody targets the DiGeorge Syndrome Critical Region Gene 6 (DGCR6), a protein encoded within the 22q11.2 chromosomal region. This region is associated with DiGeorge syndrome (DGS), a developmental disorder characterized by cardiac defects, immune deficiencies, and craniofacial abnormalities, often resulting from 22q11.2 deletions. DGCR6. along with its paralog DGCR6L, is implicated in embryonic development, though its precise molecular role remains unclear. Studies suggest it may interact with chromatin-modifying complexes or participate in transcriptional regulation, potentially influencing neural crest cell migration—a process critical for organogenesis. DGCR6 antibodies are primarily used as research tools to investigate protein expression, localization, and function in cellular and disease models. They enable detection via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Research involving DGCR6 antibodies has also explored links to psychiatric disorders (e.g., schizophrenia) tied to 22q11.2 deletions. However, commercial availability of specific, validated DGCR6 antibodies remains limited, and cross-reactivity with DGCR6L or other homologs can pose challenges. Ongoing studies aim to clarify DGCR6's biological significance and its role in 22q11.2-related pathologies.